Specifically, the authors demonstrated that this miRNA is highly expressed in ovarian cancer exosomes compared to their cells of origin, and the use of an anti-miR-1246 treatment along with the overexpression of Caveolin-1 (a miR-1246 target) was capable of sensitizing ovarian cancer cells to Paclitaxel. Here, CAV1 is linked to ovarian cancer.